NICE Updates Medical Cannabis Guidance for Chronic Pain

The National Institute for Health and Care Excellence (NICE) has issued updated clinical guidance on the use of medical cannabis for the management of chronic pain in the United Kingdom. The revision reflects an expanding body of clinical evidence and addresses longstanding calls from patient advocates and specialist clinicians for clearer prescribing pathways.

What Has Changed

The updated guidance broadens the criteria under which specialist physicians can consider cannabis-based medicinal products (CBMPs) for patients experiencing moderate-to-severe chronic pain that has not responded adequately to conventional treatments. This includes neuropathic pain, fibromyalgia, and complex regional pain syndrome.

NICE has emphasised that prescribing should remain within specialist services and that patients should be enrolled in a formal monitoring programme to track outcomes. The guidance also stresses that decisions must be made on an individual basis following a thorough review of prior treatment history.

Impact on UK Patients

For the estimated 28 million adults in the UK living with chronic pain, this update represents a meaningful step forward. Many patients have previously struggled to access CBMPs due to a lack of clarity around eligibility and a shortage of trained prescribers.

• Broader eligibility criteria for neuropathic and musculoskeletal pain conditions
• Clearer guidance for GPs on when to refer patients to specialist pain clinics
• Formal registry requirements for patient outcome tracking
• Recommendations on product selection, including THC:CBD ratios for pain management

How to Access Medical Cannabis for Chronic Pain

Patients interested in pursuing medical cannabis for chronic pain should speak with their GP in the first instance. While GPs cannot prescribe CBMPs directly, they can initiate referrals to specialist pain services or independent medical cannabis clinics. You can use our clinic finder to identify accredited services near you.

When attending a consultation, patients should bring documentation of prior treatments tried, including dosage information and evidence of inadequate response. A comprehensive treatment history strengthens the case for a cannabis-based alternative.

What This Means for Prescribers

The updated NICE guidance provides clearer professional backing for prescribers who have been cautious about recommending CBMPs. With more robust clinical frameworks in place, the number of licensed prescribers is expected to grow significantly over the coming months.

For patients wishing to explore their options, the THC vs CBD guide on LeafMe explains the key differences between product types and which formulations tend to be most effective for chronic pain conditions.